Investigating the Potential of Transmucosal Delivery of Febuxostat from Oral Lyophilized Tablets Loaded with a Self-Nanoemulsifying Delivery System

Gout is the most familiar inflammatory arthritis condition caused by the elevation of uric acid in the bloodstream. Febuxostat (FBX) is the latest drug approved by the United States Food and Drug Administration (US FDA) for the treatment of gout and hyperuricemia. FBX is characterized by low solubil...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Amodi, Yasir A., Hosny, Khaled M, Alharbi, Waleed S., Safo, Martin K., El-Say, Khalid M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7356236/
https://www.ncbi.nlm.nih.gov/pubmed/32531910
http://dx.doi.org/10.3390/pharmaceutics12060534

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7356236/
https://www.ncbi.nlm.nih.gov/pubmed/32531910
http://dx.doi.org/10.3390/pharmaceutics12060534

Ejemplares similares